PIK3CA and colorectal cancer: Initially, we determined the potency of PI3K pathway inhibitors in a panel of 29 human colorectal cancer cell lines, in order to aid selection of exemplars for further analysis (Supplementary Table 1–2; Supplementary Fig. 1).